Literature DB >> 10773966

Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I: Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome.

L Llorente1, Y Richaud-Patin, A Díaz-Borjón, C Alvarado de la Barrera, J Jakez-Ocampo, H de la Fuente, R Gonzalez-Amaro, E Diaz-Jouanen.   

Abstract

BACKGROUND: Multidrug resistance (MDR) is characterized by overexpression of P-glycoprotein, a pump molecule that decreases intracellular drug concentrations by increasing drug efflux from cells.
OBJECTIVE: To look for correlations between clinical status and P-glycoprotein activity and/or TNF-alpha mRNA levels in patients with rheumatoid arthritis.
METHODS: Sixteen patients were studied. Based on response to therapy, eight were refractory and eight nonrefractory to treatment. Findings were compared to those in 24 healthy controls. Flow cytometry was used to evaluate P-glycoprotein activity in peripheral blood mononuclear cells isolated by gradient centrifugation and incubated with the P-glycoprotein substrate daunorubicin. TNF-alpha mRNA levels were determined using quantitative PCR.
RESULTS: Patients with rheumatoid arthritis showed an increased number of lymphocytes with high P-glycoprotein activity (p = 0.0001) as compared to the normal controls. P-glycoprotein activity was higher in the refractory than in the non-refractory patient subgroup (p = 0.006). Also, TNF-alpha mRNA levels were markedly higher in the refractory subgroup than in the nonrefractory subgroup, and were undetectable in the normal controls.
CONCLUSIONS: Enhanced P-glycoprotein activity may be closely related to an unfavorable clinical course and a poor response to treatment. Increased TNF-alpha expression and chronic exposure to various drugs, including glucocorticoids, may contribute to increase P-glycoprotein activity. Both high P-glycoprotein activity and excessive amounts of TNF-alpha seem associated with poor outcome in rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10773966

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  20 in total

Review 1.  Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?

Authors:  Vasco C Romão; Aurea Lima; Miguel Bernardes; Helena Canhão; João Eurico Fonseca
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

2.  Clinical relevance of P-glycoprotein activity on peripheral blood mononuclear cells and polymorphonuclear neutrophils to methotrexate in systemic lupus erythematosus patients.

Authors:  Mario García-Carrasco; Claudia Mendoza-Pinto; Salvador Macías-Díaz; Ivet Etchegaray-Morales; Socorro Méndez-Martínez; Pamela Soto-Santillán; Beatriz Pérez-Romano; Erick A Jiménez-Herrera; Omar Guzmán-Ruiz; Alejandro Ruiz-Argüelles
Journal:  Clin Rheumatol       Date:  2017-06-14       Impact factor: 2.980

3.  GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia.

Authors:  Martin Stanulla; Elke Schäffeler; Stefan Arens; Anke Rathmann; André Schrauder; Karl Welte; Michel Eichelbaum; Ulrich M Zanger; Martin Schrappe; Matthias Schwab
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

Review 4.  Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?

Authors:  P Ranganathan; S Eisen; W M Yokoyama; H L McLeod
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

5.  Effect of prostaglandin E2 on multidrug resistance transporters in human placental cells.

Authors:  Clifford W Mason; Gene T Lee; Yafeng Dong; Helen Zhou; Lily He; Carl P Weiner
Journal:  Drug Metab Dispos       Date:  2014-09-26       Impact factor: 3.922

6.  Association of the MDR1 3435 polymorphism in patients with refractory rheumatoid arthritis in a Chinese population.

Authors:  Jinwei Chen; Lixiao Chen; Ni Mao; Yiming Liu
Journal:  Rheumatol Int       Date:  2011-09-24       Impact factor: 2.631

7.  The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs.

Authors:  Marek Drozdzik; Tomasz Rudas; Andrzej Pawlik; Mateusz Kurzawski; Bogusław Czerny; Wanda Gornik; Magdalena Herczynska
Journal:  Eur J Clin Pharmacol       Date:  2006-08-24       Impact factor: 2.953

8.  Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug.

Authors:  S L Hider; A Owen; R Hartkoorn; S Khoo; D Back; A J Silman; I N Bruce
Journal:  Ann Rheum Dis       Date:  2006-02-27       Impact factor: 19.103

Review 9.  Neuroendocrine-immune interactions in rheumatoid arthritis: mechanisms of glucocorticoid resistance.

Authors:  Marni N Silverman; Esther M Sternberg
Journal:  Neuroimmunomodulation       Date:  2008-07-29       Impact factor: 2.492

Review 10.  Disease control by regulation of P-glycoprotein on lymphocytes in patients with rheumatoid arthritis.

Authors:  Shizuyo Tsujimura; Yoshiya Tanaka
Journal:  World J Exp Med       Date:  2015-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.